Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Arkansas

CNS medication trials in Arkansas

59 CNS medication studies are recruiting participants at sites in 6 cities across Arkansas as of November 17, 2026, according to ClinicalTrials.gov.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Arkansas city with a recruiting study

By research area: Schizophrenia (19), Depression (17), Migraine (6), Bipolar Disorder (5), ADHD (4), Epilepsy (4), Parkinson's Disease (4).

Little Rock (48), Bentonville (11), Bryant (8), Rogers (7), Glenwood (1), Hot Springs (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Depression: recently updated in Arkansas

Basic details from each study's public record (the 12 most recently updated of 59). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Recruiting in
    Rogers
    Registry record
    NCT07226661 · updated
  2. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Recruiting in
    Little Rock
    Registry record
    NCT07592689 · updated
  3. Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

    • Phase 3
    • Ages 10 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Recruiting in
    Little Rock
    Registry record
    NCT06372964 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Arkansas on ClinicalTrials.gov.

Schizophrenia: recently updated in Arkansas

  1. A Study to Evaluate the Effect of KarXT on Urological Safety

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Little Rock
    Registry record
    NCT07221877 · updated
  2. A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia

    • Phase 1
    • Ages 18 to 65
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Recruiting in
    Bentonville
    Registry record
    NCT07908680 · updated
  3. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Recruiting in
    Little Rock
    Registry record
    NCT06229210 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Arkansas on ClinicalTrials.gov.

Bipolar disorder: recently updated in Arkansas

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Little Rock · Rogers
    Registry record
    NCT06951711 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Arkansas on ClinicalTrials.gov.

ADHD: recently updated in Arkansas

  1. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Phase 3
    • Ages 6 to 11
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Recruiting in
    Little Rock
    Registry record
    NCT07717879 · updated
  2. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Recruiting in
    Little Rock
    Registry record
    NCT07717892 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Arkansas on ClinicalTrials.gov.

Parkinson's disease: recently updated in Arkansas

  1. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Recruiting in
    Little Rock
    Registry record
    NCT06989112 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Arkansas on ClinicalTrials.gov.

Epilepsy: recently updated in Arkansas

  1. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Recruiting in
    Bentonville
    Registry record
    NCT07594119 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Arkansas on ClinicalTrials.gov.

Migraine: recently updated in Arkansas

  1. A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Recruiting in
    Little Rock
    Registry record
    NCT07816367 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Arkansas on ClinicalTrials.gov.

Ask about studies in Arkansas

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call